Jazz Pharmaceuticals plc (JAZZ)
Jazz Pharmaceuticals: Pipeline Setback While Business Transition Continues
Jazz Pharmaceuticals plc's suvecaltamide failed in a phase 2b trial for essential tremor, but this is a minor setback for the company and one that should have been expected. The oxybate franchise is performing well despite generic Xyrem and Lumryz competition, and Jazz is seeing healthy patient and net sales growth of Xywav. Jazz expects to deliver 4% to 9% revenue growth in 2024.
Why Is Jazz Pharmaceuticals Stock Trading Lower On Thursday?
Thursday, Jazz Pharmaceuticals plc JAZZ released topline results from the Phase 2b trial evaluating the efficacy and safety of suvecaltamide (JZP385), an investigational, highly selective and state-dependent modulator of T-type calcium channels, in adult patients with essential tremor (ET).
Jazz Pharmaceuticals' tremor drug fails to meet main goal in mid-stage study
Jazz Pharmaceuticals said on Thursday its experimental drug to treat a neurological condition that causes involuntary and rhythmic shaking failed to meet the main goal in a mid-stage study.
Why Is Jazz (JAZZ) Down 3.5% Since Last Earnings Report?
Jazz (JAZZ) reported earnings 30 days ago. What's next for the stock?
3 Cheap Blue-Chip Stocks to Buy Now: May 2024
If the market's dramatic shifts this year leave you discombobulated, you're not alone. But, despite widespread overvaluation across a range of tech stocks, plenty of cheap blue-chip stocks are ready to offer the portfolio stability we're all desperately seeking.
